Testing a pill for non-alcoholic fatty liver disease
Part of Digestive system, Hormones & metabolism clinical trials.
This trial tests a diabetes drug called empagliflozin to see if it can reduce fat and inflammation in the liver in people with a specific type of fatty liver disease called NASH. It may help if you have NASH and either have type 2 diabetes or don't have it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with a type of fatty liver disease called NASH, confirmed by a liver biopsy within the last 3 months.
- You either have type 2 diabetes or you do not, but we will test for it.
- Your HbA1c (a blood sugar test) is less than or equal to 80 mmol/mol.
- If you could become pregnant, you must agree to use two reliable forms of birth control.
- You must not have certain other liver diseases, or heavy alcohol use (men: more than 2 drinks per day, women: more than 1 drink per day).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two diabetes pills (pioglitazone and empagliflozin) to see if they can reduce liver fat in people with type 2 diabetes and fatty liver disease. It may help if your diabetes is not well controlled and you have a fatty liver confirmed by a special ultrasound scan.
This study tests whether a medicine called empagliflozin (a type of SGLT2 inhibitor) can help treat non-alcoholic fatty liver disease in adolescents with obesity. It aims to see if the drug can reduce fat in the liver and improve liver health.
This trial studies whether erugliflozin can reduce liver fat and liver scarring (fibrosis) while also improving blood sugar in people with type 2 diabetes and fatty liver disease (NASH/NAFLD). It’s designed for people who haven’t used certain diabetes medicines like SGLT2 inhibitors or insulin before.
This study tests a medication called empagliflozin (a type of SGLT2 inhibitor) to see if it can help treat fatty liver disease in teenagers and young adults. It may improve liver health and help with weight management.
This study compares two common medications—empagliflozin (a diabetes drug) and statins (cholesterol-lowering drugs)—to see which works better for people with fatty liver disease who also have diabetes and high cholesterol. It aims to find a treatment that helps improve liver health while also managing these related conditions.
This study tests whether a medicine called henagliflozin can help reduce fat in the liver for people with type 2 diabetes and non-alcoholic fatty liver disease. It may help improve liver health and blood sugar control at the same time.
Hear when a new Liver Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.